Literature DB >> 15164945

Effect of melatonin on the oxidative stress in N1E-115 cells is not mediated by mt1 receptors.

P Montilla1, M Feijóo, M C Muñoz, J R Muñoz-Castañeda, I Bujalance, I Túnez.   

Abstract

To explore if protective effect of melatonin on oxidative stress induced by okadaic acid, an inhibitor of protein phosphatases PP1 and PP2A, is mediated by membrane receptors subtype mt1, we used an in vitro model with N1E-115 neuroblastoma cells. We demonstrated that exposure of cells to 50 nM okadaic acid for 2 h induces a reduction in the activity of antioxidative enzymes, and an increase of lipid peroxidation products, while melatonin prevents the effect of okadaic acid. On the other hand, the presence of luzindole, 20 min before adding melatonin, did not cause changes on the effect of the melatonin on oxidative stress. These results seem to indicate that protective effect of melatonin is not mediated by mt1 receptors.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 15164945     DOI: 10.1007/bf03179883

Source DB:  PubMed          Journal:  J Physiol Biochem        ISSN: 1138-7548            Impact factor:   4.158


  20 in total

Review 1.  Neurotoxic and synaptic effects of okadaic acid, an inhibitor of protein phosphatases.

Authors:  R Tapia; F Peña; C Arias
Journal:  Neurochem Res       Date:  1999-11       Impact factor: 3.996

2.  Activation of p38 mitogen-activated protein kinase and mitochondrial Ca(2+)-mediated oxidative stress are essential for the enhanced expression of grp78 induced by the protein phosphatase inhibitors okadaic acid and calyculin A.

Authors:  K D Chen; M T Lai; J H Cho; L Y Chen; Y K Lai
Journal:  J Cell Biochem       Date:  2000-01       Impact factor: 4.429

3.  Oxidative stress as a mechanism for quinolinic acid-induced hippocampal damage: protection by melatonin and deprenyl.

Authors:  W M Behan; M McDonald; L G Darlington; T W Stone
Journal:  Br J Pharmacol       Date:  1999-12       Impact factor: 8.739

4.  Catalase in vitro.

Authors:  H Aebi
Journal:  Methods Enzymol       Date:  1984       Impact factor: 1.600

Review 5.  The oxidant/antioxidant network: role of melatonin.

Authors:  R J Reiter; D X Tan; J Cabrera; D D'Arpa; R M Sainz; J C Mayo; S Ramos
Journal:  Biol Signals Recept       Date:  1999 Jan-Apr

6.  Oxygen reactive radicals production in cell culture by okadaic acid and their implication in protein synthesis inhibition.

Authors:  W G Matias; A Traore; M Bonini; A Sanni; E E Creppy
Journal:  Hum Exp Toxicol       Date:  1999-10       Impact factor: 2.903

7.  Selective MT2 melatonin receptor antagonists block melatonin-mediated phase advances of circadian rhythms.

Authors:  M L Dubocovich; K Yun; W M Al-Ghoul; S Benloucif; M I Masana
Journal:  FASEB J       Date:  1998-09       Impact factor: 5.191

8.  The neuroprotective activities of melatonin against the Alzheimer beta-protein are not mediated by melatonin membrane receptors.

Authors:  Miguel A Pappolla; Marcia J Simovich; Tara Bryant-Thomas; Yau-Jan Chyan; Burkhard Poeggeler; Margarita Dubocovich; Roger Bick; George Perry; Felix Cruz-Sanchez; Mark A Smith
Journal:  J Pineal Res       Date:  2002-04       Impact factor: 13.007

9.  The protein-phosphatase inhibitor okadaic acid mimics MSH-induced and melatonin-reversible melanosome dispersion in Xenopus laevis melanophores.

Authors:  B Cozzi; M D Rollag
Journal:  Pigment Cell Res       Date:  1992-09

10.  Expression cloning of a high-affinity melatonin receptor from Xenopus dermal melanophores.

Authors:  T Ebisawa; S Karne; M R Lerner; S M Reppert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

View more
  3 in total

Review 1.  Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases.

Authors:  Raquel L Arribas; Alejandro Romero; Javier Egea; Cristóbal de Los Ríos
Journal:  Br J Pharmacol       Date:  2018-06-19       Impact factor: 8.739

2.  Melatonin in Alzheimer's disease and other neurodegenerative disorders.

Authors:  V Srinivasan; S R Pandi-Perumal; D P Cardinali; B Poeggeler; R Hardeland
Journal:  Behav Brain Funct       Date:  2006-05-04       Impact factor: 3.759

Review 3.  Melatonin Therapy in Patients with Alzheimer's Disease.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Luis I Brusco
Journal:  Antioxidants (Basel)       Date:  2014-04-10
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.